Both HDGFL2 and MYO18A CE-containing transcripts were found to be significantly elevated in postmortem frontal cortex tissues from FTLD-TDP patients, and their cryptic peptides were detected in cerebrospinal fluid (CSF) from patients with ALS or FTD, suggesting these cryptic peptides and others may serve as stable fluid biomarkers of TDP-43 dysfunction [7]. This evidence concerns the gene HDGFL2 and frontotemporal dementia.